TPST חוב כולל להון Tempest Tx

The current market quotes for Tempest Therapeutics (TPST) visualized below demonstrate financial resilience amid growing demand for drugs targeting solid tumors and liver cancer. The individual debt-to-equity ratio stands at 0.00. Tempest Therapeutics (TPST) develops small molecules for immune management in oncology, leveraging a powerful scientific resource. Simultaneously, the business is implementing environmental filters and conserving water in its laboratories.

For Tempest Therapeutics (TPST), whose model relies on costly oncology R&D without current revenue, the debt-to-equity ratio chart reflects the funding stability of its pipeline. This ratio compares total liabilities to net asset value, determining the degree of dependence on borrowed funds and the risk of capital degradation amid price volatility or changes in Fed rates.